share_log

Entheon Biomedical Acquires Lobo Genetics, Inc. in Bid to Strengthen Screening and Treatment Evaluation Tech for Psychedelics

Entheon Biomedical Acquires Lobo Genetics, Inc. in Bid to Strengthen Screening and Treatment Evaluation Tech for Psychedelics

Entheon Biomedical公司收购Lobo Genetics公司以加强迷幻药的筛选和治疗评估技术
Benzinga Real-time News ·  2021/10/06 09:24

Image Provided by Wiki Commons

图片由Wiki Commons提供

Entheon Biomedical Corp. (OTCQB:ENTBF), the biotech research and development company focused on developing DMT-based treatments for addiction and substance use disorders, announced its acquisition of Lobo Genetics, Inc., a Toronto-based personalized genetics company, for 5 million common shares. 

Entheon Biomedical Corp.(场外交易代码:ENTBF)是一家生物技术研发公司,专注于开发基于DMT的成瘾和物质使用障碍治疗方法,该公司宣布收购Lobo Genetics,Inc.,一家总部位于多伦多的个性化遗传学公司,收购500万股普通股。

The deal is part of Entheon’s larger mission to develop a slate of effective and objective tools for predicting and measuring treatment outcomes on an individual patient basis. Here’s why that matters and how Entheon is working to achieve that goal.

这笔交易是Entheon更大使命的一部分,该使命是开发一系列有效和客观的工具,用于预测和衡量单个患者的治疗结果。这就是为什么这很重要,以及Entheon是如何努力实现这一目标的。

The Need for Objective Tools to Predict and Measure Psychedelic Treatment Outcomes

需要客观的工具来预测和测量迷幻药物的治疗结果

After a long pause, researchers in the past decade or so have renewed interest in studying psychedelics, like Dimethyltryptamine (DMT) and ketamine, as potential treatments in mood disorders, addiction and other categories of mental illness. 

在经历了很长一段时间的停顿之后,研究人员在过去十年左右重新燃起了对迷幻剂的兴趣,比如二甲基色胺(DMT)和氯胺酮,作为治疗情绪障碍、成瘾和其他类别精神疾病的潜在疗法。

The studies that have come out over the past few decades have shown promising results. One meta-analysis of that research found that patients receiving psychedelic-assisted therapy were 80% more likely to have a positive outcome than their counterparts in the placebo control groups. Another meta-analysis found that psychedelic-assisted treatments showed significant results in patients with tobacco and alcohol dependence.

过去几十年的研究显示出了令人振奋的结果。这项研究的一项荟萃分析发现,接受迷幻辅助治疗的患者比安慰剂对照组的患者获得阳性结果的可能性高80%。另一项荟萃分析发现,迷幻辅助治疗对烟酒依赖患者有显著效果。

As promising as that research has been, however, further clinical studies and treatment development are hampered by a few key challenges. Determining the correct dose to use, predicting and preparing for the kind of experience each individual patient will have — and the limited tools available for objectively measuring treatment outcomes beyond a patient’s own reported results — are the main concerns. 

然而,尽管这项研究前景看好,但进一步的临床研究和治疗开发受到一些关键挑战的阻碍。主要关注的是确定正确的使用剂量,预测和准备每个患者将会经历的那种经历-以及除了患者自己报告的结果之外,可用于客观衡量治疗结果的有限工具。

Those challenges are precisely where Entheon has been focusing much of its efforts lately. By exploring the potential for genetics testing and other tools, the biotech company aims to develop a portfolio of screening and diagnostics tools that can lead to more precision dosing and more accurate predictions of which patients are the best candidates for psychedelic-assisted therapies.

这些挑战正是Entheon最近一直在集中精力的地方。通过探索遗传学测试和其他工具的潜力,这家生物技术公司的目标是开发一系列筛查和诊断工具,以实现更精确的剂量测定,并更准确地预测哪些患者最适合接受迷幻辅助治疗。

Lobo Genetics Inc Acquisition Adds Direct-to-Consumer Screening Platform to Entheon Portfolio

收购Lobo Genetics Inc.为Entheon产品组合增加了直接面向消费者的筛查平台

Earlier this year, Entheon already announced the launch of the industry’s first genetics testing kit for evaluating a person’s potential outcomes with psychedelics. The HaluGen kit was developed in partnership with Lobo Genetics, which Entheon acquired in July. 

今年早些时候,Entheon已经宣布推出业界第一个基因测试试剂盒,用于评估一个人使用迷幻剂的潜在结果。这个HaluGen套件是与Lobo Genetics合作开发的,Lobo Genetics于7月被Entheon收购。

While the test is mostly meant to screen patients before deciding on treatment, it’s an important preliminary tool in helping researchers and patients identify who the best candidates for psychedelic-assisted therapy are.

虽然这项测试主要是为了在决定治疗之前对患者进行筛查,但它是帮助研究人员和患者确定谁是最适合进行迷幻辅助治疗的重要初步工具。

Entheon Sponsors Clinical Research Into Using EEG Data to Measure Treatment Response

Entheon赞助使用脑电图数据衡量治疗反应的临床研究

In addition to screening platforms like the HaluGen kit, Entheon is also looking into tools to help measure outcomes during and after a psychedelic treatment program. In August, the company announced that it was sponsoring a clinical study by Heading Health to evaluate the potential of using electroencephalograph (EEG) data to objectively measure a patient’s response to psychedelic treatment.

除了像HaluGen试剂盒这样的筛查平台外,Entheon还在研究帮助测量迷幻治疗计划期间和之后结果的工具。今年8月,脑电图仪公司宣布将赞助一项由Head Health发起的临床研究,以评估使用脑电图数据客观衡量患者对迷幻药物治疗反应的潜力。

The Heading Health study will look at ketamine, but Entheon hopes to extend that research to other molecules, including DMT, later on. Researchers will monitor EEG data in patients during a ketamine treatment session with an eye toward finding out whether and which EEG biomarker data can predict long-term response to the treatment. 

标题健康研究将着眼于氯胺酮,但Entheon希望稍后将这一研究扩展到其他分子,包括DMT。研究人员将在氯胺酮治疗期间监测患者的脑电图数据,以找出是否以及哪些脑电图生物标志物数据可以预测治疗的长期反应。

Building a Powerful Data-Driven AI to Build and Monitor Treatment Plans

构建强大的数据驱动型人工智能来构建和监控治疗计划

Ultimately, Entheon aims to combine that genetics data from the Lobo Genetics acquisition with the EEG data from the Heading Health study to develop Entheon IQ™, the company’s treatment algorithm. 

最终,Entheon的目标是将收购Lobo Genetics的遗传学数据与标题健康研究的脑电图数据结合起来,开发该公司的治疗算法Entheon IQ™。

The Entheon IQ™ platform will use AI and machine learning to evaluate patient data to generate insights on correct dosing, provide real-time feedback during treatment and help healthcare providers and patients develop a post-therapy support system. 

Entheon IQ™平台将使用人工智能和机器学习来评估患者数据,以生成对正确剂量的见解,在治疗过程中提供实时反馈,并帮助医疗保健提供者和患者开发治疗后支持系统。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发